Stock 2126 JW (CAYMAN) THERAPEUTICS CO. LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings JW (Cayman) Therapeutics Co. Ltd

Equities

2126

KYG5210T1040

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:06 30/04/2024 pm IST 		5-day change 1st Jan Change
1.79 HKD -1.65% Intraday chart for JW (Cayman) Therapeutics Co. Ltd +4.07% -20.80%
20/03 JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023 MT
20/03 JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
JW (CAYMAN) THERAPEUTICS CO. LTD Stock JW (Cayman) Therapeutics Co. Ltd
-20.80% 93.83M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.46% 102B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 96.29B
B+
ARGENX SE Stock argenx SE
+2.13% 22.18B
B
BIONTECH SE Stock BioNTech SE
-15.84% 21.2B
B+
GENMAB A/S Stock Genmab A/S
-9.21% 18.31B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.38B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.65% 16.36B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.39% 13.97B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+31.35% 12.17B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2126 Stock
  4. Ratings JW (Cayman) Therapeutics Co. Ltd